Nasus Pharma vs Trulieve Cannabis
Nasus Pharma and Trulieve Cannabis are similar in size: $1.24bn and $1.18bn of revenue in their latest fiscal years. Nasus Pharma kept more of each dollar of sales as profit: a net margin of -0.5% against -9.9%. Nasus Pharma carries less debt relative to equity (0.0% against 12.3%).
| Latest fiscal year | Nasus PharmaNSRX, 2025 | Trulieve CannabisTRLV, 2025 |
|---|---|---|
| Revenue | $1.24bn | $1.18bn |
| Revenue growth | — | -0.4% |
| Net income | −$5.9m | −$116m |
| Operating margin | -0.4% | 12.1% |
| Net margin | -0.5% | -9.9% |
| Return on equity | — | -9.7% |
| Free cash flow | −$4.9m | $229m |
| Cash | $1.2m | $256m |
| Total debt | $0 | $141m |
| Debt to equity | 0.0% | 12.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 5,000 |
| Market value | $28.6m | $2.20bn |
| Price vs our value range | — | Below our value range |
| Moat score | — | 28 (Weak) |
| Insider trades, 12 months | 3 buys, 0 sales | 0 buys, 7 sales |